Akebia Therapeutics

Akebia receives $22 million in Series B

Tuesday, April 26, 2011

Ohio-based Akebia Therapeutics, a pharmaceutical discovery and development company focused on anemia and vascular disorders, has closed a $22 million Series B Preferred stock financing. The round was led by the company’s existing investors: Novartis Venture Fund and Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital as well as new investors.

[Read More]